WO2000071107A8 - New pharmaceutical combinations for nos inhibitors - Google Patents

New pharmaceutical combinations for nos inhibitors

Info

Publication number
WO2000071107A8
WO2000071107A8 PCT/IB2000/000295 IB0000295W WO0071107A8 WO 2000071107 A8 WO2000071107 A8 WO 2000071107A8 IB 0000295 W IB0000295 W IB 0000295W WO 0071107 A8 WO0071107 A8 WO 0071107A8
Authority
WO
WIPO (PCT)
Prior art keywords
sleep
disorders
nos
nos inhibitors
pharmaceutical combinations
Prior art date
Application number
PCT/IB2000/000295
Other languages
French (fr)
Other versions
WO2000071107A2 (en
Inventor
Mario David Saltarelli
John Adams Lowe Iii
Original Assignee
Pfizer Prod Inc
Mario David Saltarelli
John Adams Lowe Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK1660-2001A priority Critical patent/SK16602001A3/en
Priority to APAP/P/2001/002326A priority patent/AP2001002326A0/en
Application filed by Pfizer Prod Inc, Mario David Saltarelli, John Adams Lowe Iii filed Critical Pfizer Prod Inc
Priority to BR0010820-0A priority patent/BR0010820A/en
Priority to IL14595500A priority patent/IL145955A0/en
Priority to AU29353/00A priority patent/AU2935300A/en
Priority to EP00907891A priority patent/EP1178784A1/en
Priority to EEP200100611A priority patent/EE200100611A/en
Priority to PL00358538A priority patent/PL358538A1/en
Priority to KR1020017014884A priority patent/KR20020010916A/en
Priority to HU0301287A priority patent/HUP0301287A3/en
Priority to MXPA01011978A priority patent/MXPA01011978A/en
Priority to CA002374668A priority patent/CA2374668A1/en
Priority to EA200101110A priority patent/EA200101110A1/en
Priority to JP2000619414A priority patent/JP2003523941A/en
Publication of WO2000071107A2 publication Critical patent/WO2000071107A2/en
Priority to IS6126A priority patent/IS6126A/en
Priority to NO20015651A priority patent/NO20015651L/en
Priority to HR20010862A priority patent/HRP20010862A2/en
Priority to BG06208A priority patent/BG106208A/en
Publication of WO2000071107A8 publication Critical patent/WO2000071107A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne de nouvelles combinaisons pharmaceutiques pour des composés présentant une activité comme inhibiteur de l'oxyde nitrique-synthase (NOS). Cette invention concerne plus particulièrement l'utilisation d'inhibiteurs de NOS, notamment des inhibiteurs de NOS neuronaux (N-NOS) sélectifs: seuls ou en combinaison avec un autre agent actif, en particulier, un antagoniste de récepteur SSRI ou NK-1, pour le traitement de troubles ou d'états pathologiques. Le traitement pouvant être déclenché ou facilité par modification des rythmes circadiens. Entre autres exemples de tels troubles ou états pathologiques figurent : la cécité, l'obésité, les troubles affectifs saisonniers, les troubles bipolaires, le décalage horaire, les troubles du rythme circadien du sommeil, le manque de sommeil, la parasomnie, les troubles du sommeil paradoxal, l'hypersomnie, les troubles du cycle sommeil-éveil, la narcolepsie et les troubles du sommeil liés au travail en équipe ou aux horaires de travail irréguliers ; l'enurésie nocturne et le syndrome d'Ekbom.The present invention relates to novel pharmaceutical combinations for compounds having activity as a nitric oxide synthase (NOS) inhibitor. This invention relates more particularly to the use of NOS inhibitors, in particular selective neural NOS inhibitors (N-NOS): alone or in combination with another active agent, in particular an SSRI or NK-1 receptor antagonist, for the treatment of disorders or medical conditions. Treatment can be triggered or facilitated by modifying circadian rhythms. Other examples of such disorders or medical conditions include: blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythm disorder, lack of sleep, parasomnia, sleep disorders REM sleep, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders related to teamwork or irregular work schedules; nocturnal enuresis and Ekbom syndrome.

PCT/IB2000/000295 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors WO2000071107A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
MXPA01011978A MXPA01011978A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors.
HU0301287A HUP0301287A3 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
CA002374668A CA2374668A1 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
APAP/P/2001/002326A AP2001002326A0 (en) 1999-05-21 2000-03-16 New pharmaceuticals combinations for nos inhibitors.
AU29353/00A AU2935300A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
EP00907891A EP1178784A1 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
EEP200100611A EE200100611A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations of NOS inhibitors
PL00358538A PL358538A1 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
KR1020017014884A KR20020010916A (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
SK1660-2001A SK16602001A3 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for NOS inhibitors
IL14595500A IL145955A0 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors
BR0010820-0A BR0010820A (en) 1999-05-21 2000-03-16 Pharmaceutical combinations for nos inhibitors
EA200101110A EA200101110A1 (en) 1999-05-21 2000-03-16 NEW PHARMACEUTICAL COMBINATIONS OF NOS INHIBITORS
JP2000619414A JP2003523941A (en) 1999-05-21 2000-03-16 Novel pharmaceutical combinations for NOS inhibitors
IS6126A IS6126A (en) 1999-05-21 2001-10-26 New pharmaceutical compositions for NOS lazy
NO20015651A NO20015651L (en) 1999-05-21 2001-11-20 New pharmaceutical combinations for NOS inhibitors
HR20010862A HRP20010862A2 (en) 1999-05-21 2001-11-20 New pharmaceutical combinations for nos inhibitors
BG06208A BG106208A (en) 1999-05-21 2001-12-11 New pharmaceutical combinations for nos inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13552099P 1999-05-21 1999-05-21
US60/135,520 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000071107A2 WO2000071107A2 (en) 2000-11-30
WO2000071107A8 true WO2000071107A8 (en) 2002-01-24

Family

ID=22468464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000295 WO2000071107A2 (en) 1999-05-21 2000-03-16 New pharmaceutical combinations for nos inhibitors

Country Status (33)

Country Link
EP (1) EP1178784A1 (en)
JP (1) JP2003523941A (en)
KR (1) KR20020010916A (en)
CN (1) CN1617743A (en)
AP (1) AP2001002326A0 (en)
AR (1) AR022640A1 (en)
AU (1) AU2935300A (en)
BG (1) BG106208A (en)
BR (1) BR0010820A (en)
CA (1) CA2374668A1 (en)
CO (1) CO5160295A1 (en)
DZ (1) DZ3041A1 (en)
EA (1) EA200101110A1 (en)
EE (1) EE200100611A (en)
GT (1) GT200000071A (en)
HN (1) HN2000000045A (en)
HR (1) HRP20010862A2 (en)
HU (1) HUP0301287A3 (en)
IL (1) IL145955A0 (en)
IS (1) IS6126A (en)
MA (1) MA26732A1 (en)
MX (1) MXPA01011978A (en)
NO (1) NO20015651L (en)
OA (1) OA11943A (en)
PA (1) PA8494601A1 (en)
PE (1) PE20010157A1 (en)
PL (1) PL358538A1 (en)
SK (1) SK16602001A3 (en)
TN (1) TNSN00106A1 (en)
TR (1) TR200103351T2 (en)
UY (1) UY26148A1 (en)
WO (1) WO2000071107A2 (en)
ZA (1) ZA200109555B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001785A1 (en) * 2000-01-18 2001-07-19 Boehringer Ingelheim Pharma Use of NK-1 receptor antagonists for treatment of restless legs syndrome
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
DOP2002000467A (en) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-AMINO-6 (PHENYL REPLACED IN POSITIONS 2,4,5) -PIRIDINES
CN100368409C (en) * 2003-06-24 2008-02-13 神经研究公司 Novel 8-aza-bicyclo not 3.2.1|octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
EP2152271B1 (en) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
WO2008148851A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CN101678019B (en) 2007-06-08 2016-03-30 詹森药业有限公司 Piperidine/piperazine derivatives
WO2009147170A2 (en) 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
WO2010101246A1 (en) 2009-03-05 2010-09-10 塩野義製薬株式会社 Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3983392A4 (en) * 2019-06-14 2023-12-06 SRX Cardio, LLC Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)

Also Published As

Publication number Publication date
TNSN00106A1 (en) 2005-11-10
JP2003523941A (en) 2003-08-12
EA200101110A1 (en) 2002-08-29
BR0010820A (en) 2002-03-05
AP2001002326A0 (en) 2001-12-31
EP1178784A1 (en) 2002-02-13
HUP0301287A3 (en) 2005-03-29
CO5160295A1 (en) 2002-05-30
CA2374668A1 (en) 2000-11-30
ZA200109555B (en) 2004-04-07
IS6126A (en) 2001-10-26
BG106208A (en) 2002-09-30
AR022640A1 (en) 2002-09-04
DZ3041A1 (en) 2004-03-27
NO20015651D0 (en) 2001-11-20
AU2935300A (en) 2000-12-12
HN2000000045A (en) 2001-03-02
HUP0301287A2 (en) 2003-08-28
WO2000071107A2 (en) 2000-11-30
IL145955A0 (en) 2002-07-25
KR20020010916A (en) 2002-02-06
MA26732A1 (en) 2004-12-20
NO20015651L (en) 2002-01-18
EE200100611A (en) 2003-02-17
PE20010157A1 (en) 2001-02-16
TR200103351T2 (en) 2002-06-21
GT200000071A (en) 2001-11-08
CN1617743A (en) 2005-05-18
PL358538A1 (en) 2004-08-09
HRP20010862A2 (en) 2003-06-30
MXPA01011978A (en) 2002-05-06
OA11943A (en) 2006-04-12
PA8494601A1 (en) 2002-08-29
UY26148A1 (en) 2000-12-29
SK16602001A3 (en) 2003-03-04

Similar Documents

Publication Publication Date Title
WO2000071107A8 (en) New pharmaceutical combinations for nos inhibitors
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
MXPA05013224A (en) Pyridinyl carbamates as hormone-sensitive lipase inhibitors.
JP2005532372A5 (en)
MA27142A1 (en) PIPERAZINE DERIVATIVES HAVING ANTAGONIST ACTIVITY OF CCR1 RECEPTORS
EA200901492A1 (en) Treatment of benign prostatic hyperplasia by the selective modulator of the androgen receptor (sarm)
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
MXPA04004797A (en) Indole-2-carboxamides as factor xa inhibitors.
BR9810841A (en) Alicyclic metalloprotease inhibitors
MA30324B1 (en) BENZIMIDAZOLES WITH ACTIVITY AT THE M1 RECEPTOR AND THEIR USE IN MEDICINE
ATE454372T1 (en) AGENTS ACTIVE ON THE HISTAMINE H3 RECEPTOR, PRODUCTION AND THERAPEUTIC APPLICATIONS
TW200510393A (en) New indole derivatives as factor Xa inhibitors
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
HK1092135A1 (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo [3.2.0]heptane is an effective analgesic agent
NO990433L (en) New compounds and compositions for the treatment of diseases associated with tryptase activity
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
RU2004103746A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INTERSTITIAL CYSTITIS
BR9910899A (en) N- (hetero-aralkyl) -azaeterocyclamide sulfonic or sulfonylamino compounds
TW324662B (en) Benzamide-containing pharmaceutical composition
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
IL172134A0 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP1315496B1 (en) The treatment of inflammatory disorders
US20070259945A1 (en) Method for treating pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807878.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 514763

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000907891

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 29353/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 16602001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2374668

Country of ref document: CA

Ref document number: 20010893

Country of ref document: UZ

Kind code of ref document: A

Ref document number: 2374668

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 619414

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20010862A

Country of ref document: HR

Ref document number: PV2001-4165

Country of ref document: CZ

Ref document number: 1200101133

Country of ref document: VN

Ref document number: P-825/01

Country of ref document: YU

Ref document number: 200101110

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011978

Country of ref document: MX

Ref document number: 1020017014884

Country of ref document: KR

Ref document number: 2001/03351

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 106208

Country of ref document: BG

Kind code of ref document: A

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
WWP Wipo information: published in national office

Ref document number: 1020017014884

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000907891

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-4165

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014884

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-4165

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 2000907891

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000907891

Country of ref document: EP